Search research articles
Contact Us
Filters
Showing results (51-60 of 57) with videos related to
Page
of 6
Sort By:
You have reached the last page of results.
This site can display upto 57 results.
Clinical and Translational Science
|
February 14, 2022
Phase I and scintigraphy studies to evaluate safety, tolerability, pharmacokinetics, and lung deposition of inhaled GDC-0214 in healthy volunteers
Rui Zhu, Hubert Chen, Joshua Galanter, et al.
The Journal of Allergy and Clinical Immunology
|
March 21, 2021
Inhaled JAK inhibitor GDC-0214 reduces exhaled nitric oxide in patients with mild asthma: A randomized, controlled, proof-of-activity trial
Irene E Braithwaite, Fang Cai, Jennifer A Tom, et al.
The New England Journal of Medicine
|
December 14, 2022
Trial of Beremagene Geperpavec (B-VEC) for Dystrophic Epidermolysis Bullosa
Shireen V Guide, Mercedes E Gonzalez, I Sinem Bağcı, et al.
Critical Care Medicine
|
December 15, 2022
Astegolimab or Efmarodocokin Alfa in Patients With Severe COVID-19 Pneumonia: A Randomized, Phase 2 Trial
Michael Waters, James A McKinnell, Andre C Kalil, et al.
Pulmonary Pharmacology & Therapeutics
|
June 1, 2022
Effects of inhaled JAK inhibitor GDC-4379 on exhaled nitric oxide and peripheral biomarkers of inflammation
Hubert Chen, Rebecca Kunder, Yixuan Zou, et al.
Critical Care (London, England)
|
June 13, 2023
Early plasma angiopoietin-2 is prognostic for ARDS and mortality among critically ill patients with sepsis
Carrie M Rosenberger, Katherine D Wick, Hanjing Zhuo, et al.
Scientific Reports
|
April 3, 2022
A whole genome sequencing study of moderate to severe asthma identifies a lung function locus associated with asthma risk
Diana Chang, Julie Hunkapiller, Tushar Bhangale, et al.
Page
of 6
Search research articles
Search
Showing results (51-60 of 57) with videos related to
Sort By:
Page
of 6
You have reached the last page of results.
This site can display upto 57 results.
Clinical and Translational Science
|
February 14, 2022
Phase I and scintigraphy studies to evaluate safety, tolerability, pharmacokinetics, and lung deposition of inhaled GDC-0214 in healthy volunteers
Rui Zhu, Hubert Chen, Joshua Galanter, et al.
The Journal of Allergy and Clinical Immunology
|
March 21, 2021
Inhaled JAK inhibitor GDC-0214 reduces exhaled nitric oxide in patients with mild asthma: A randomized, controlled, proof-of-activity trial
Irene E Braithwaite, Fang Cai, Jennifer A Tom, et al.
The New England Journal of Medicine
|
December 14, 2022
Trial of Beremagene Geperpavec (B-VEC) for Dystrophic Epidermolysis Bullosa
Shireen V Guide, Mercedes E Gonzalez, I Sinem Bağcı, et al.
Critical Care Medicine
|
December 15, 2022
Astegolimab or Efmarodocokin Alfa in Patients With Severe COVID-19 Pneumonia: A Randomized, Phase 2 Trial
Michael Waters, James A McKinnell, Andre C Kalil, et al.
Pulmonary Pharmacology & Therapeutics
|
June 1, 2022
Effects of inhaled JAK inhibitor GDC-4379 on exhaled nitric oxide and peripheral biomarkers of inflammation
Hubert Chen, Rebecca Kunder, Yixuan Zou, et al.
Critical Care (London, England)
|
June 13, 2023
Early plasma angiopoietin-2 is prognostic for ARDS and mortality among critically ill patients with sepsis
Carrie M Rosenberger, Katherine D Wick, Hanjing Zhuo, et al.
Scientific Reports
|
April 3, 2022
A whole genome sequencing study of moderate to severe asthma identifies a lung function locus associated with asthma risk
Diana Chang, Julie Hunkapiller, Tushar Bhangale, et al.
Page
of 6